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The success of anticancer chemotherapy relies at least in part on the induction of an immune response against tumor
cells. Thus, tumors growing on mice that lack the pattern recognition receptor TLR4 or the purinergic receptor P2RX7 fail
to respond to chemotherapy with anthracyclins or oxaliplatin in conditions in which the same neoplasms growing on
immunocompetent mice would do so. Similarly, the therapeutic efficacy (measured as progression-free survival) of
adjuvant chemotherapy with anthracyclins is reduced in breast cancer patients bearing loss-of-function alleles of TLR4 or
P2RX7. TLR4 loss-of-function alleles also have a negative impact on the therapeutic outcome of oxaliplatin in colorectal
cancer patients. Here, we report that loss-of-function TLR4 and P2RX7 alleles do not affect overall survival in non-small cell
lung cancer (NSCLC) patients, irrespective of the administration and type of chemotherapy. The intrinsic characteristics of
NSCLC (which near-to-always is chemoresistant and associated with poor prognosis) and/or the type of therapy that is
employed to treat this malignancy (which near-to-always is based on cisplatin) may explain why two genes that affect
the immune response to dying cells fail to influence the clinical progression of NSCLC patients.
Introduction
There is ever expanding evidence suggesting that the escape from
immune surveillance is a fundamental hallmark of cancer
1,2 and
that therapeutic interventions with cytotoxic compounds or
targeted anticancer agents are successful only when they re-
establish an immune control on cancer growth.
3-5 Transplantable
or primary murine cancers respond to chemotherapy with
anthracyclins or oxaliplatin much more efficiently when they
grow in syngenic immunocompetent mice than in immunodefi-
cient hosts.
6,7 In line with this finding, clinical studies revealed
that severe lymphopenia negatively affects the response of solid
tumors to chemotherapy.
8 Moreover, while tumors growing
on immunocompetent mice respond to chemotherapy with
anthracyclins or oxaliplatin, tumors that grow on hosts lacking T
cells, important cytokines [such as interleukin 1  (IL-1 ), IL-17A
and interferon c] or their receptors continue to proliferate in an
unperturbed fashion.
7,9,10 Thus, at least in some settings, immune
defects are negative predictors of the response to chemotherapy.
Successful chemotherapeutics can induce a type of tumor cell
death that is immunogenic,
11-13 implying that the patient’s dying
cancer cells function as a therapeutic vaccine, thereby eliciting an
antitumor immune response that controls or eliminates the residual
(chemotherapy-resistant) disease.
5,14 We have reported in the past
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RESEARCH PAPERthat immunogenic cell death (ICD) is characterized by the pre-
apoptotic exposure of calreticulin (CRT) on the cell surface,
15-17 the
active secretion of ATP during the blebbing phase of apoptosis,
9,18,19
andthepost-apoptoticreleaseofthechromatin-bindingnon-histone
protein high mobility group B1 (HMGB1).
20 CRT, ATP and
HMGB1 interact with CD91, purinergic P2RX7 receptors
and Toll-like receptor 4 (TLR4), respectively, on the surface of
dendritic cells, thuspromotingthe engulfment of dying cells or their
debris,
21,22 the production of IL-1 
9,23 and cross-presentation of
tumor antigens to T cells,
7,24 respectively.
Mice lacking P2rx7 or Tlr4 phenocopy mice devoid of T cells
(such as athymic nu/nu mice or mice injected with antibodies
that deplete CD4
+ and CD8
+ T cells) in thus far that tumors
growing on P2rx7
2/2 or Tlr4
2/2 mice do not respond to
chemotherapy with anthracyclins or oxaliplatin in conditions in
which the same neoplasms growing on normal, immunocompe-
tent animals do so.
7,9,10,20 Similarly, adjuvant chemotherapy
exhibits a reduced efficacy in patients bearing loss-of-function
alleles of P2RX7 or TLR4. This has been shown for patients with
the single-nucleotide polymorphism (SNP) rs4986790 in TLR4
(1307A G; Asp299Gly; NM_138554.3:c.896A . G) and
rs3751143 in P2RX7 (1513A C; Glu496Ala; NM_002562.4:
c.1487A . C).
7,9,10,20
The Asp299Gly substitution (corresponding to SNP
rs4986790) impairs the affinity of TLR4 for lipopolysaccharide
(LPS) and reportedly reduces the LPS-driven tumor necrosis
factor a (TNFa) production by monocytes in vitro.
25 At a clinical
level, SNP rs4986790 has been associated with a reduced
frequency of chronic obstructive pulmonary disease,
26 but
increased incidence of chronic sarcoidosis.
27 Operable breast
cancer patients with one single lymph node invasion (but no
distant metastasis) that are homozygous or heterozygous for SNP
rs4986790 exhibit accelerated relapse upon anthracyclin-based
chemotherapy as compared with patients bearing the wild type
genotype.
7 Similarly, in a cohort of patients with colorectal cancer
treated with oxaliplatin, homozygous or heterozygous carriers
of SNP rs4986790 exhibited a more rapid relapse than age- and
sex-matched patients bearing the wild type allele.
10 The
Glu496Ala substitution (corresponding to SNP rs3751143) limits
the affinity of P2RX7 for ATP and renders patient-derived,
Mycobacterium-infected macrophages resistant against ATP-
induced cell death. This is most pronounced for macrophages
derived from homozygous subjects,
28 although some effect is also
seen in the context of heterozygosity.
29 Subjects that carry one or
two copies of SNP rs3751143 exhibit an enhanced susceptibility
to extrapulmonary tuberculosis
29 and toxoplasmic retinochoroi-
ditis,
30 confirming the functional impact of this polymorphism at
the clinical level. Moreover, among breast cancer patients bearing
two copies of the wild type TLR4 allele, homozygous or
heterozygous carriers of the P2RX7 rs3751143 exhibited a more
rapid relapse than age- and sex-matched patients who carried the
wild type allele only.
9
Based on these premises, we decided to evaluate the impact of
the aforementioned TLR4 and P2RX7 alleles on the survival of
patients with non-small cell lung cancer (NSCLC).
Results and Discussion
We took advantage of patient material from the phase III
International Adjuvant Lung Cancer Trial (IALT), which
compared cisplatin-based chemotherapy to no treatment in
patients with resected stage-I-IIIA NSCLC, leading to the
conclusion that adjuvant therapy can delay a substantial number
of deaths,
31 at least in a subset of patients.
32,33 DNA from tumor
specimens was extracted, yielding sufficient material to analyze the
absence or presence (homo- or heterozygosity) of TLR4
rs4986790 and P2RX7 rs3751143 in 705 and 748 patients,
respectively (Table 1). Subsequently, we compared patients that
were homozygous for the wild type alleles of TLR4 (Fig.1;
Table 2) or P2RX7 (Fig.2; Table 2) with those bearing one or
two copies of the loss-of-function alleles, and then plotted the
Kaplan-Meier survival curves for all patients included in the study
(Figs.1A and 2A), for patients that received chemotherapy
(Figs.1B and 2B) and for patients that did not (Figs.1C and
2C). We found that neither SNP rs4986790 in TLR4 nor SNP
rs3751143 in P2RX7 impact on the overall survival of NSCLC
patients included in the IALT study. This held true when the
entire patient population was analyzed (Figs.1A and 2A), as well
as upon the stratification of patients based on their allocation
to chemotherapy (Fig.1B and C; Fig.2B and C). Stratification
Table1. Statistical analysis of the IALT cohort
TLR4 P2RX7
Variable Wild type
(n = 460)
Mutated
(n = 245)
Total
(n = 705)
Univariate p
(trend test p)
Wild type
(n = 445)
Mutated
(n = 303)
Total
(n = 748)
Univariate p
(trend test p)
n (%) n (%) n (%) n (%) n (%) n (%)
Sex 0.48 0.97
Female 88 (19.1) 43 (17.6) 131 (18.6) 80 (18.0) 58 (19.1) 138 (18.4)
Male 372 (80.9) 202 (82.4) 574 (81.4) 365 (82.0) 245 (80.9) 610 (81.6)
Age (years) , 0.001* 0.07
, 55 150 (32.6) 69 (28.2) 219 (31.1) 122 (27.4) 103 (34.0) 225 (30.1) (0.02)
55–64 218 (47.4) 88 (35.9) 306 (43.4) 194 (43.6) 132 (43.6) 326 (43.6)
. 64 92 (20.0) 88 (35.9) 180 (25.5) 129 (29.0) 68 (22.4) 197 (26.3)
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TLR4 P2RX7
Variable Wild type
(n = 460)
Mutated
(n = 245)
Total
(n = 705)
Univariate p
(trend test p)
Wild type
(n = 445)
Mutated
(n = 303)
Total
(n = 748)
Univariate p
(trend test p)
n (%) n (%) n (%) n (%) n (%) n (%)
Stage 0.93 0.43
I 151 (32.8) 89 (36.3) 240 (34.0) (0.71) 145 (32.6) 110 (36.3) 255 (34.1) (0.55)
II 110 (23.9) 56 (22.9) 166 (23.5) 102 (22.9) 74 (24.4) 176 (23.5)
III 199 (43.3) 100 (40.8) 299 (42.4) 198 (44.5) 119 (39.3) 317 (42.4)
N of TNM 0.61 0.20
0 202 (43.9) 122 (49.8) 324 (46.0) (0.34) 202 (45.4) 142 (46.9) 344 (46.0) (0.83)
1 136 (29.6) 70 (28.6) 206 (29.2) 124 (27.9) 94 (31.0) 218 (29.1)
2 122 (26.5) 53 (21.6) 175 (24.8) 119 (26.7) 67 (22.1) 186 (24.9)
T of TNM 0.83 1.00
1 69 (15.0) 37 (15.1) 106 (15.0) (0.68) 68 (15.3) 48 (15.8) 116 (15.5) (0.93)
2 278 (60.4) 142 (58.0) 420 (59.6) 266 (59.8) 178 (58.7) 444 (59.4)
3 113 (24.6) 66 (26.9) 179 (25.4) 111 (24.9) 77 (25.4) 188 (25.1)
Histology 0.70 0.77
Adenocarcinoma 157 (34.1) 75 (30.6) 232 (32.9) 141 (31.7) 98 (32.3) 239 (32.0)
Other NSCLC 55 (12.0) 32 (13.1) 87 (12.3) 59 (13.3) 35 (11.6) 94 (12.6)
Squamous cell carcinoma 248 (53.9) 138 (56.3) 386 (54.8) 245 (55.1) 170 (56.1) 415 (55.5)
Surgery 0.49 0.29
Lobe- or segmentectomy 278 (60.4) 144 (58.8) 422 (59.9) 270 (60.7) 178 (58.7) 448 (59.9)
Pneumonectomy 182 (39.6) 101 (41.2) 283 (40.1) 175 (39.3) 125 (41.3) 300 (40.1)
WHO PS** 0.54 0.01
0 259 (56.3) 132 (53.9) 391 (55.5) (0.33) 220 (49.4) 19 (63.7) 413 (55.2) (, 0.001)
1 163 (35.4) 93 (38.0) 256 (36.3) 182 (40.9) 94 (31.0) 276 (36.9)
2 38 (8.3) 20 (8.2) 58 (8.2) 43 (9.7) 16 (5.3) 59 (7.9)
Lymphoid infiltration 0.55 0.04
Intense 52 (11.3) 25 (10.2) 77 (10.9) 40 (9.0) 43 (14.2) 83 (11.1)
Weak 408 (88.7) 220 (89.8) 628 (89.1) 405 (91.0) 260 (85.8) 665 (88.9)
Pleural invasion 0.80 0.61
No 422 (91.7) 223 (91.0) 645 (91.5) 406 (91.2) 279 (92.1) 685 (91.6)
Yes 38 (8.3) 22 (9.0) 60 (8.5) 39 (8.8) 24 (7.9) 63 (8.4)
Vascular invasion 0.73 0.74
No 318 (69.1) 172 (70.2) 490 (69.5) 313 (70.3) 215 (71.0) 528 (70.6)
Yes 142 (30.9) 73 (29.8) 215 (30.5) 132 (29.7) 88 (29.0) 220 (29.4)
Lymphatic invasion 0.39 0.42
No 139 (30.2) 81 (33.1) 220 (31.2) 133 (29.9) 99 (32.7) 232 (31.0)
Yes 321 (69.8) 164 (66.9) 485 (68.8) 312 (70.1) 204 (67.3) 516 (69.0)
Quality after final H&E 0.30 0.98
Average 46 (10.0) 32 (13.1) 78 (11.1) 47 (10.6) 34 (11.2) 81 (10.8)
Good 414 (90.0) 213 (86.9) 627 (88.9) 398 (89.4) 269 (88.8) 667 (89.2)
*Significant p values are indicated in italic. p values were calculated by two-sided x
2 tests, using logistic regressions stratified on center. **World Health
Organization (WHO) scores for performance status (PS) range from 0 to 2, with score of 0 indicating no symptoms, 1 mild symptoms and 2 moderate
symptoms. Abbreviations: H&E, hematoxylin and eosin; NSCLC, non small cell lung cancer; TNM, tumor node metastasis.
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genotype (such as heterozygosity vs. homozygosity) or
the treatment (cisplatin plus etoposide vs. cisplatin plus
microtubular inhibitors) did not reveal any consistent
impact of the analyzed TLR4 or P2RX7 polymorphisms
on patient survival (not shown). Along similar lines, a
combined analysis in which patients were classified into
groups bearing one or several loss-of-function alleles failed
to uncover any predictive or prognostic impact of TLR4
SNP rs4986790 and P2RX7 SNP rs3751143 (Fig.3,
Table 2). Intriguingly both TLR4 and P2RX7 mutational
statuses were found to be significantly associated with age,
and that of P2RX7 also with World Health Organization
(WHO) performance status and lymphoid infiltration
(Table 1).
Altogether, the data presented here indicate that loss-
of-function alleles in TLR4 and P2RX7 do not affect
overall survival in NSCLC patients, irrespective of the
administration and type of chemotherapy.
What may be the reasons for this finding, which clearly
differs from our previous observations on anthracyclin-
based adjuvant chemotherapy in breast cancer and
oxaliplatin-based adjuvant chemotherapy in colorectal
cancer?
5,7,9,10 There are at least two possible explanations
for this discrepancy. First, the prognosis of NSCLC is
intrinsically dismal,
34 and bronchial carcinomas may be
subjected to a less vigorous immunosurveillance than
tumors located in other organs such as the mammary
gland or the colic mucosa.
35 NSCLC may also be
particularly efficient in suppressing the function of
local innate immune effectors such as natural killer
(NK) cells,
36 or in escaping CD8
+ T cell-mediated
adaptive immunity (for instance due to impaired
expression and/or function of FAS).
37 Irrespective of
this, which remains a mere matter of speculation, the
literature reporting a clinical benefit from the infiltration
of NSCLC by effector T cells is relatively scarce as
compared with the plethora of reports demonstrating
that mammary and colorectal cancers are controlled by
a clinically relevant level of immunosurveillance.
5,38,39
Of note, it appears that the infiltration of the tumor
mass by dendritic cells has a more positive impact on
NSCLC prognosis than that by effector T cells.
40 These
latter findings, together with recent results from the
largest multicentric NSCLC gene profiling study to
date, the NIH Director’s Challenge Study,
41 support
further investigations on the role of the immune
system in NSCLC and on its relevance during the
response to chemotherapy. Second, the standard treat-
ment for NSCLC is based on cisplatin, a DNA damag-
ing agent that, besides being associated with a high
rate of relapse due to the development of chemoresis-
tance,
42 induces non-immunogenic cell death.
10 This means
that cells succumbing to cisplatin in vitro fail to elicit specific
anticancer immune responses when inoculated in vivo.
43,44
Accordingly, the response to cisplatin of experimental cancers in
vivo is not influenced by the absence or presence of TLR4.
10
Of note, cisplatin is usually combined with other chemother-
apeutic agents that are also unable to induce ICD, such as
etoposide,
15,45 or with microtubular inhibitors, whose capacity to
Figure1. Kaplan-Meier estimates of overall survival in non-small cell lung
carcinoma (NSCLC) patients bearing one or two copies of the TLR4 rs4986790 SNP
(mutated TLR4) or the wild type allele only (wild type TLR4). Overall survival
according to TLR4 status in all 705 patients (A), in patients subjected to
chemotherapy (B) and in untreated patients (C).
274 OncoImmunology Volume 1 Issue 3induce ICD has not yet been thoroughly evaluated. Importantly,
our findings do not rule out a role for TLR4 and P2XR7 in the
pathogenesis and response to therapy of NSCLC, as multiple
epigenetic mechanisms, including promoter hypermethylation,
alternative splicing and microRNA-mediated gene regulation,
might be responsible for the functional inhibition of these two
proteins. Future studies investigating the how the innate and
cognate immune systems influence the clinical progression of
NSCLC will surely provide deeper insights into the results of our
retrospective analysis.
Materials and Methods
Patients and study design. One-thousand-eight-hundred-sixty-
seven patients were enrolled in the IALT study, upon informed
consent. The clinical features of the patient cohort can be found
elsewhere.
31 Paraffin-embedded tumor blocks (obtained at the
time of surgery) were collected in 14 distinct countries by 28
medical centers that participated into the IALT study with more
than ten patients.
32 Approval was obtained by local institutional
review boards according to the national regulations. A total of 867
samples were reviewed at the Centre Hospitalier Universitaire
Albert Michallon (Grenoble, France) and histopathologically
classified according to the system adopted by the World Health
Organization (WHO) in 2004. The amount and quality of 822
among the 867 paraffin blocks were judged adequate for
experimental procedures. Finally, 776 samples were identified as
non-small cell lung cancer (NSCLC), but only 705 and 748 were
available for TLR4 and P2RX7 genotyping, respectively.
Genotyping. Genomic DNA was isolated from paraffin-
embedded tumors by means of the DNeasy Blood and Tissue
Kit (Qiagen). Gene-specific Taqman
1 primers and genotype-
specific probes (Applied Biosystems) were used to amplify a TLR4
fragment containing the Asp299Gly single nucleotide polymorph-
ism (rs4986790) site and a P2RX7 fragment containing the
Glu496Ala polymorphism (rs3751143). Genotypes were deter-
mined by comparing the signals from fluorescent probes (FAM
and VIC) and by calculating the natural logarithm of the ratio
between the FAM and VIC signals [log (FAM/VIC)].
Statistical analysis. All statistical analyses were performed
with long-term survival data,
46 by means of the SAS software,
version 9.2 (SAS Institute). Conditional logistic regression on an
aggregate center variable was used for both univariate and
multivariate analyses. Survival rates were estimated using the
Table2. Overall survival according to treatment and mutational status
Group All patients Treated patients Untreated patients
Population with wild type TLR4
Deaths/total n° of patients 298/460 149/230 149/230
Median OS - months 4.1 4.4 3.8
Population with mutated TLR4
Deaths/total n° of patients 144/245 85/130 59/115
Median OS - months 4.6 4.5 5.6
HR* for death (95% CI) 0.81 (0.66–0.99) 0.85 (0.64–1.13) 0.73 (053–1.01)
p value 0.04 0.27 0.06
Population with wild type P2RX7
Deaths/total n° of patients 281/445 150/232 131/213
Median OS - months 4.4 4.6 3.9
Population with mutated P2RX7
Deaths/total n° of patients 187/303 99/157 88/146
Median OS - months 4.5 4.3 4.7
HR* for death (95% CI) 1.03 (0.85–1.24) 1.06 (0.81–1.38) 1.00 (0.76–1.32)
p value 0.77 0.68 1.00
Population with wild type TLR4 and P2RX7
Deaths/total n° of patients 162/241 83/124 79/117
Median OS - months 4.0 4.3 3.5
Population with at least one TLR4 or P2RX7 mutation
Deaths/total n° of patients 263/436 145/228 118/208
Median OS - months 4.6 4.5 5.2
HR* for death (95% CI) 0.84 (0.68–1.03) 0.86 (0.65–1.15) 0.80 (0.59–1.08)
p value 0.09 0.32 0.14
*Hazard ratios (HR) reflect the comparison between the mutated and the wild type groups. All hazard ratios were adjusted for sex, age, tumor stage,
histology type and the presence or absence of pleural invasion, and were stratified according to clinical center. Abbreviations: CI, confidence interval; OS,
overall survival.
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values of the TLR4 and P2RX7 status
and chemotherapy were studied using a
Cox model taking into account every
factor used in the stratified random
assignment (center, tumor stage, type of
surgery) plus clinical and histological
prognostic factors (age, sex, WHO perform-
ance status, nodal status, lymphoid infiltra-
tion and revised histopathological type), as
in previous IALT-based studies,
32 as well as
all factors that werestatistically relatedto the
biomarker status in the multivariate logistic
model (p , 0.05). All reported p values
were two sided and only p values , 0.001
were considered statistically significant, to
minimize the risk of false-positive results.
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